7 Einträge gefunden

1. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

   1. Huebner, Hanna
   2. Kurbacher, Christian M
   3. Kuesters, Geoffrey
   4. Hartkopf, Andreas D
   5. Lux, Michael P
   6. Huober, Jens
   7. Volz, Bernhard

   2020 - Forschungsinformationssystem des UKE
2. HER2-targeted therapy influences CTC status in metastatic breast cancer

   1. Deutsch, Thomas M
   2. Riethdorf, Sabine
   3. Fremd, Carlo
   4. Feisst, Manuel
   5. Nees, Juliane
   6. Fischer, Chiara
   7. Hartkopf, Andreas D

   2020 - Forschungsinformationssystem des UKE
3. Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer:New Treatments and Implementation of Therapies with Companion Diagnostics

   1. Lüftner, Diana
   2. Schneeweiss, Andreas
   3. Hartkopf, Andreas D
   4. Müller, Volkmar
   5. Wöckel, Achim
   6. Janni, Wolfgang
   7. Ettl, Johannes

   2020 - Forschungsinformationssystem des UKE
4. Update Breast Cancer 2020 Part 1 - Early Breast Cancer:Consolidation of Knowledge About Known Therapies

   1. Schneeweiss, Andreas
   2. Hartkopf, Andreas D
   3. Müller, Volkmar
   4. Wöckel, Achim
   5. Lux, Michael P
   6. Janni, Wolfgang
   7. Ettl, Johannes

   2020 - Forschungsinformationssystem des UKE
5. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab

   1. Michel, Laura L
   2. Hartkopf, Andreas D
   3. Fasching, Peter A
   4. Kolberg, Hans-Christian
   5. Hadji, Peyman
   6. Tesch, Hans
   7. Häberle, Lothar

   2020 - Forschungsinformationssystem des UKE
6. Update Breast Cancer 2020 Part 3 - Early Breast Cancer

   1. Huober, Jens
   2. Schneeweiss, Andreas
   3. Hartkopf, Andreas D
   4. Müller, Volkmar
   5. Lux, Michael P
   6. Janni, Wolfgang
   7. Ettl, Johannes

   2020 - Forschungsinformationssystem des UKE
7. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

   1. Schneeweiss, Andreas
   2. Ettl, Johannes
   3. Lüftner, Diana
   4. Beckmann, Matthias W
   5. Belleville, Erik
   6. Fasching, Peter A
   7. Fehm, Tanja N

   2020 - Forschungsinformationssystem des UKE